Keyword: Sandoz

Following an EpiPen generic launch by Teva, Novartis' Sandoz has released its launch plans for epinephrine alternative Symjepi.

Following a handful of deals for other biosimilar drugmakers, Pfizer decided to settle its Humira patent fight with AbbVie.

A U.S. biotech that bought nearly 30 generic drugs from Sandoz in January says it has plans to build its first manufacturing facility in China.

Just one day after Novartis laid out plans for its Alcon spinoff, it found itself fending off a rumor that it also intends to wave goodbye to Sandoz.

Months after world regulators first discovered impurities in the ingredient of a Chinese ingredient maker, tainted drugs continue to show up in the U.S. supply.

Coherus won an FDA nod for its biosimilar to Amgen's Neulasta, heating up the market share fight—and touching off predictions of price competition.

After suffering an earlier rejection for its biosimilar to Roche's Rituxan, Sandoz has now decided to abandon the drug.

Sandoz is prepping its second hackathon, this time at SXSW, scouting ideas that use digital tech to tackle a local health problem.

AbbVie has inked a fourth patent deal on its megablockbuster Humira that forces Novartis to the back of the line for a U.S. launch.

Novartis' Sandoz is stirring things up in the epinephrine market—and it's about to stir things up in the pediatric epinephrine market, too.